What is UTHR's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 23.20B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for UTHR?

P/E (TTM) is 17.44 and 52-week range is $409.07 to $609.35 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s UTHR figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for UTHR?

The company profile lists revenue (TTM) near $2.92B, net income (TTM) near $1.22B, EPS (TTM) near $27.96 when available from the market-data feed. Figures are informational and may lag live markets.

Where is United Therapeutics Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in Silver Spring, Maryland, US, 42.5M shares outstanding, ISIN US91307C1027 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

United Therapeutics Corp

$UTHR

Health Care · Biotechnology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. The company is headquartered in Silver Spring, Maryland and currently employs 1,400 full-time employees. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.

Employees

1,400

Website

www.unither.com/

IPO

1999-06-17

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)